Incidence and risk of rash to mTOR inhibitors in cancer patients-a meta-analysis of randomized controlled trials

Acta Oncologica

Volumn 54, Issue 1, 2015, Pages 124-132

  Shameem, Raji ^a   Lacouture, Mario ^b   Wu, Shenhong ^c,d  

^a LENOX HILL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; EXEMESTANE; LETROZOLE; OCTREOTIDE; PLACEBO; TEMSIROLIMUS; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANGIOMYOLIPOMA; ARTICLE; ASTROCYTOMA; BODY SURFACE; BREAST CANCER; BULLOUS DERMATITIS; CANCER PATIENT; DESQUAMATION; ERYTHEMA; ERYTHRODERMA; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; PAPULAR RASH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW; VESICULAR RASH; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG ERUPTIONS; EXANTHEMA; INCIDENCE; RISK;

DRUG ERUPTIONS; EVEROLIMUS; EXANTHEMA; HUMANS; INCIDENCE; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84919651080     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.923583     Document Type: Article

References (25)

1. Dabney R, Devine R, Sein N, George B. New agents in renal cell carcinoma. Target Oncol Epub 2013 Nov 16
2. Yuan R, Kay A, Berg WJ, Lebwohl D. T argeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45
3. Khokhar NZ, Altman JK, Platanias LC. E merging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opinion Oncol 2011;23:578-86
4. Martins F, de Oliveira M. A, Wang Q, Sonis S, Gallottini M, George S, et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013;49:293-8
5. Carpenter JT, Roche H, Campone M, Colomer R, Jagiello-Gruszfeld A, Moore L, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCL-779) in combination with letrozole in post-menopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2007;23 :16s: abstract 564
6. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. New Engl J Med 2011;364:514-23
7. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis placebo-controlled trial. Lancet 2013;1:817-24
8. Ohtsu A, Ajani JA, Bai YX, Bany YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013;31:3935-43
9. Motzer R. J, Escudier B, Oudard S, Hutson T. E, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010;116:4256-65
10. Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex phase 3 trial. Lancet 2013;1:125-32
11. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormonereceptor-positive advanced breast cancer. New Engl J Med 2012;366:520-9
12. Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol 2012;30:2718-24
13. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009;27:2630-7
14. Pavel M. E, Hainsworth J. D, Baudin E, Peeters M, Horsh D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-12
15. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New Engl J Med 2007;356:2271-81
16. Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013;31:195-202
17. Balagula Y, Rosen S. T, Lacouture M. E. The emergence of supportive oncodermatology: The study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 2011;65:624-35
18. Ramirez-Fort M. K, Case E. C, Rosen AC, Cerci F. B, Wu S, Lacouture ME, et al. Rash to the mTOR inhibitor everolimus systematic review and meta-analysis. Am J Clin Oncol Epub 2012 Dec 13
19. Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis. Eur J Cancer 2012;48:340-6
20. Hadoux J, Vignot S, De La M otte Rouge T. R enal cell carcinoma: Focus on safety and efficacy of temsirolimus. Clinical medicine insights. Oncology 2010;4:143-54
21. Balagula Y, Rosen A, Tan BH, Busam KJ, Pulitzer MP, Motzer RJ, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer 2012;118:5078-83
22. Gandhi M, Kuzel T, Lacouture M. E osinophilic rash secondary to temsirolimus. Clin Genitour Cancer 2009;7:E34-6
23. Staehler M, Haseke N, Khoder W, Stief C. G. Profile of temsirolimus in the treatment of advanced renal cell carcinoma. Onco Targets Ther 2010;3:191-6
24. Paplomata E, Zelnak A, O R egan R. Everolimus: Side effect profi le and management of toxicities in breast cancer. Breast Cancer Res Treat 2013;140:453-62
25. Chen A. P, Setser A, Anadkat MJ, Cotliar J, Olsen E. A, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012;67:1025-39